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Take home" message:  CD117 expression in human ILC2s depends on the local tissue milieu 




Although innate lymphoid cells (ILC)1s, ILC2s and ILC3s are emerging as important cell 
populations regulating tissue homeostasis, remodelling and inflammation, a vast majority of 
our knowledge stems from in vitro and murine experiments, and requires thorough 
confirmation in human diseases. 
Relative levels of ILCs were evaluated by means of flow cytometry in freshly resected human 
upper airways mucosa of patients with chronic rhinosinusitis (CRS) without nasal polyps 
(NP) (CRSsNP) and with nasal polyps (CRSwNP), taking into account the patient’s clinical 
parameters and disease comorbidities.  
We report that the CD117 and IL-1RI expression status of human ILC2s depends on the local 




 ILC2s - exclusively present in CRSwNP - possess 
an interrelationship with Th2 cytokine and eosinophil levels in human upper airway mucosa. 




 ILC2s are increased, yielding lower eosinophilia in this 
disease despite the high levels of ILC2s.  




 fractions within the native human ILC2 
population are not a random phenomenon in contrast to what could be concluded from in 
vitro data, and that the IL-1RI expression is not ubiquitous in ILC2s in vivo in humans, which 







Chronic rhinosinusitis (CRS) is a heterogeneous group of chronic airway inflammatory 
diseases affecting the mucosa of the nasal and paranasal cavities and is either accompanied 
by polyp formation (CRSwNP) or is presented without polyps (CRSsNP) [1]. CRS shows a 
high prevalence of up to 15% in adults, often leading to the subsequent development of lower 
respiratory tract conditions, especially asthma [2]. CRSsNP and CRSwNP are distinct disease 
entities with CRSwNP being associated with a T-helper 2 (Th2)-skewed eosinophilic 
inflammation with high interleukin (IL)-5 and eosinophil cationic protein (ECP) 
concentrations in the polyps, while CRSsNP is characterized by a more predominant Th1 
milieu with pronounced levels of interferon (IFN)-γ in the inflamed ethmoidal mucosa [1]. 
Furthermore, novel evidence indicates considerable heterogeneity within the CRSwNP 
subgroup, determining the risk of co-morbid asthma. Despite continuous research progress 
that contributes to further unveil the pathophysiology of these chronic airway conditions, the 
etiology remains poorly understood and appears to be multifactorial.  
 
Over the last years a new class of innate effector cells whose development relies on signalling 
through the IL-2 receptor (IL-2R) common γ chain and IL-7Rα (CD127) has drawn much 
attention. These cells are referred to as helper innate lymphoid cells (ILCs) [3-5]. In contrast 
to T and B cells, this ILC lineage does not express recombined, antigen-specific receptors and 
is substantially represented at barrier surfaces. Based on the expression of lineage-defining 
transcription factors and on their functional similarities to T helper cells, 3 subsets of helper 
ILCs can be discriminated, being arranged over 3 global ILC groups. 
 
Group 1 ILCs include besides an IFN-γ-secreting helper ILC subset, referred to as ILC1s, 
also the cytotoxic conventional natural killer (cNK) cells and intraepithelial type 1 innate 
lymphoid cells (ieILC1s). ILC1s produce IFN-γ on activation with IL-12, IL-15, and IL-18. 
They have been shown to be implicated in the defence against viruses, bacteria, and protozoa. 
ILC1s are reported to be predominantly present in chronically inflamed mucosal tissues, 
while being absent under normal physiology. [6] Group 2 ILCs currently only consists of 
ILC2s that secrete the typical Th2 cell-associated cytokines IL-4, IL-5, IL-9 and IL-13. They 
also produce amphiregulin, a member of the epidermal growth factor family involved in 
limiting and repairing tissue damage. ILC2s are involved during early immune responses to 
helminth infection, but are also important for allergen-induced airway inflammation and 
tissue repair. ILC2s can be activated by various cytokines, such as IL-33, IL-25, thymic 
stromal lymphopoietin (TSLP), and IL-1β, as well as lipid mediators such as eicosanoids, 
including prostaglandin D2 (PGD2) and leukotriene D4 (LTD4) [7]. Group 3 ILCs again 
comprise different populations including lymphoid tissue inducer (LTi) cells, natural 
cytotoxicity receptor (NCR)
+
 ILC3s and NCR
-




 ILC3 fractions 
produce IL-22 and IL-17, respectively, and are regarded as defenders of mucosal barrier 
function implicated in immunity against extracellular bacteria and autoimmune diseases. 
Both cell populations produce cytokines upon activation by IL-1β and IL-23 [4, 5]. LTi cells 
are important in formation of lymph nodes during fetal development [8]. 
 
Upon their initial characterization, ILC2s were reported to be abundantly present in the upper 
airway mucosa of CRSwNP patients [9], and sinonasal tissues became popular to translate 
mechanistic findings into the research of ILCs. However, most translational parts of these 
studies were performed on a low number of patients reporting no or limited clinical data, 
consequently also not taking into account the potential effect of comorbidities [9-11]. 
Moreover, the presence of the other ILC subpopulations in upper airway mucosa of CRSsNP 
patients has received less attention.  
 
In the present report we show that in non-inflamed conditions, ILC1s are the most prominent 
ILCs in sinonasal tissue. In CRSwNP, ILC1s are decreased while ILC2s per se are not 




 fractions within the ILC2s, and taking 





 ILC2s levels are explicitly increased in CRSwNP, showing an 










The patients’ clinical data can be found in Table 1. More detailed information can be found in 
the Online Data Supplement. 
 
Flow cytometry staining 
Tissue native ILCs were gated as living, lymphogate CD45
+




























































 for the NCR
+
 fraction, as based on a 
previously reported gating strategy [12] and according to the gating strategy shown in Fig E1 
in the Online Data Supplement. The levels of the different ILC subpopulations are expressed 
as percentage of the total living cells. See the Online Supplement for more methodological 
details.  
 
In vitro assessment of the functional responses by freshly isolated ILC2s  
The single cells were re-suspended in tissue culture medium supplemented by IL-2 (5ng/ml). 
The cells were activated with 50 ng/ml PMA (Sigma) and 1 µg/ml ionomycin (Sigma) for 3 
hours at 37°C in the presence of 5% CO2. 1 hour after the start of the PMA/iono treatment, 
Brefeldin A (5µg/ml) (ebioscience) was added. The samples were subjected to flow 





Frozen tissue samples from the same subject used for ILC flow cytometry were homogenised 
by means of mechanical disruption as described in the Online Data Supplement. 
 
Measurement of inflammatory mediators 
The inflammatory mediators IL-4, IL-5, IL-12 and IL-25 were measured on tissue 
homogenates by means of Luminex xMAP technology using the Fluorokine MAP Multiplex 
Human Cytokine kit (R&D Systems, Minneapolis, MN, USA) on a Bio-PlexTM 200 Array 
Reader (Bio-Rad, Hercules, CA, USA). Tissue ECP levels were measured by UniCAP 
(Phadia, Uppsala, Sweden) 
 
Statistical analysis 
Statistical analysis was performed by nonparametric Mann-Whitney U test. A P-value less 
than 0.05 was considered to be statistically significant (GRAPHPAD, San Diego, CA, USA). 
RESULTS 
Relative levels of ILCs in human upper airway mucosa of controls, CRSsNP and 
CRSwNP 
[9-11] 
Because the levels of CD45
+
 cells were higher in CRSsNP and CRSwNP than in controls 
(Fig E2 A), while the number of total livings cell were similar between the different subject 
groups (Fig E2 B), the flow cytometry data were expressed as a % of total living cells. In 
order to allow the reader to compare the levels of the different ILC groups to other literature 
sources where ILCs might be expressed as a % of CD45
+
 cells, in this section the results are 
presented in both ways.  
 
Members of all 3 ILC groups were present in human upper airway mucosa of all patient 
groups. In non-inflamed control conditions, ILC1s represent the most prominent subset, 
followed by NCR
-
 ILC3s, while ILC2s and NCR
+
 ILC3s showed the weakest abundance (Fig 
1 and E3). In the CRSsNP patient group, a significant increase in ILC2 and NCR
-
 ILC3 
population was observed compared to the mucosa of control subjects, whereas the levels of 
ILC1 and NCR
+
 ILC3 cells were similar (Fig 1 and E3). The inflamed mucosa of patients 
with CRSwNP contained significant lower levels of ILC1s compared to non-inflamed control 
mucosa, while the ILC2 and NCR
- 
ILC3 populations were significantly increased. NCR
+
 
ILC3 cells maintained a low level of abundance, which was similar to control mucosa (Fig 1 
and E3).  
 
ILCs in upper airway mucosa of controls, CRSsNP and CRSwNP: the effect of 
comorbidities 
As the frequently occurring CRS comorbidities allergy and asthma can potentially affect the 
levels of the ILC subsets in the mucosa, we also took these comorbidities into account.  
 
Within the non-inflamed upper airway mucosa of control individuals and within the CRSsNP 
patient group, the presence of allergy, asthma and allergic asthma had no influence on the 
number of any ILC subset (Fig 2, 3 and 4).  
The significant reduction in the levels of ILC1 cells that was observed in the undifferentiated 
CRSwNP patient group (Fig 1) can be attributed to the reduced numbers of ILC1s in 
CRSwNP patients without comorbidities and those suffering from comorbid allergy or 
comorbid asthma (Fig 2). However, and importantly, CRSwNP patients with comorbid 
allergic asthma showed no reduction in levels of ILC1 compared to the equivalent control 
patients with allergic asthma but without chronically inflamed upper airway mucosa (Fig 2).   
Unexpectedly, the levels of ILC2s were also significantly higher in the Th1 cytokine-skewed 
disease CRSsNP in comparison to the respective control patient groups. Moreover, the 
different comorbidities had no effect on the levels of ILC2 cells (Fig 3). ILC2s are not per se 
involved in the pathophysiology of CRSwNP because the inflamed mucosa of CRSwNP 
patients without comorbidities contained a similar amount of ILC2s compared to non-
inflamed mucosa of control subjects (Fig 3). The levels of ILC2s were clearly increased in 




 ILC3 levels were slightly but significantly increased in the undifferentiated 
CRSsNP and CRSwNP patient groups compared to controls (Fig 1), when comorbidities 
were taken into account, a variable outcome could be observed only yielding statistical 
significant higher levels for CRSsNP patients without comorbidities and CRSwNP with 
comorbid asthma (Fig 4A). The levels of NCR
+
 ILC3 overall remained very low in all patient 
groups with no influence by comorbidities (Fig 4B).  
 
CD117 and IL-1RI expression in the ILC2 population. 
Next we assessed the relative levels of CD117 positive and negative fractions within the 
ILC2 population [3, 5, 9] and investigated the expression of IL-1RI on ILC2 cells in view of 
the contrasting reports present in the literature [5, 10, 13-15]. 
 
Regardless of the presence or absence of allergy, asthma or allergic asthma, within the 
control subjects and the CRSsNP patient group, the majority of the ILC2 cells were CD117
-
, 
being statistically significant higher than the CD117
+
 cells, the latter virtually being absent 
(Fig 5A). In contrast, in the inflamed mucosa of CRSwNP without comorbidities, the CD117
+
 
ILC2 fraction was increased, while the CD117
-
 fraction remains on the level found in 





 ILC2 fractions in CRSwNP further increased under the influence of 
comorbid allergy and asthma (Fig 5B and C), maintaining an similar amount of cells in both 
fractions, except for the mucosa of CRSwNP patients with comorbid allergic asthma which 
possesses significantly higher numbers of CD117
-
 ILC2 compared to CD117
+
 cells (Fig 5A). 
Similar to what was observed for CD117, within the control subjects and the CRSsNP patient 
group, the majority of the ILC2 cells belonged to the IL-1RI
-
 fraction. This fraction was 
consistent significantly more pronounced than the IL-1RI
+
 fraction, which was virtually 
absent (Fig 6A). The IL-1RI
-
 ILC2 fraction was not affected by comorbid allergy and/or 
asthma (Fig 6B). For CRSwNP, the number of IL-1RI
+
 cells was clearly higher in patients 





 ILC2s in CRSwNP patients with allergy or with asthma (Fig 6A). Remarkably, the 
effect of allergy and asthma on the level of IL-1RI
+
 ILC2s did not add up in allergic 
asthmatics, showing similar levels as observed for allergic CRSwNP and asthmatic CRSwNP 
patients (Fig 6C), while the levels of IL-1RI
-
 ILC2s were increased in patients with 





 ILC2 cells were manifestly increased as a consequence of the pathological process of 
CRSwNP without comorbidities (Fig 6B and C).  
Representative figures of the gating step assessing the expression of CD117 and IL1RI on 
ILC2 cell population in controls (upper panel), CRSsNP (middle panel) and CRSwNP (lower 
panel) all suffering from comorbid allergic asthma can be found in the Online Data 









 subpopulations (Fig E5 in the Online Data Supplement). 
 
In vitro assessment of the functional responses by freshly isolated ILC2s  
See the online supplement 
  
Tissue cytokine levels 
The levels of IL-4 were slightly higher in CRSsNP and CRSwNP compared to controls, not 
reaching statistical significance (Fig 7A). Within the CRSwNP patient group, the levels of 
IL-4 were similar for each comorbidity status (fig 7A); consequently showing no parallelism 
with the number of ILC2s in CRSwNP (Fig 3, 5 and 6).  
IL-5 levels were significantly increased in all CRSwNP comorbidity subgroups versus the 
corresponding control subject groups. Within the CRSwNP patients, subjects with comorbid 
allergy, asthma and allergic asthma had significantly higher IL-5 levels than patients without 
these comorbidities. CRSsNP patients showed no significant differences (fig 7B). 
Tissue ECP levels were significantly higher in all CRSwNP comorbidity subgroups in 
comparison to the corresponding control subject groups. Within the CRSwNP patients, 
subjects with comorbid allergy, asthma and allergic asthma had significantly higher ECP 
levels than patients without these comorbidities. The levels observed in CRSsNP were also 
increased versus controls but only reaching significance for the patient group without 
comorbidities (fig 7C).  
IL-25 was only measurable in CRSwNP, yielding similar levels for every comorbidity status 
(fig 7D). IL-12 was below the detection limit for all samples (data not shown). 
  
DISCUSSION 
The observation that from the 3 ILC groups present, ILC1s are the most abundant in non-
inflamed tissues argues against the literature dogma that ILC1 cells are exclusively present 
under inflammatory conditions[6]. While this might be true for gastrointestinal tissues [16, 
17], this appears not transposable to the airway mucosa. Moreover, the opposite seems to be 
true because the inflamed CRSwNP mucosa shows lower levels of ILC1s than control 
mucosa. As CRSwNP is particularly known as a Th2 cytokine-skewed eosinophilic 
inflammatory condition with high IL-5 and eosinophil cationic protein (ECP) concentrations 
in the polyps [1], reduced ILC1 levels seem to be consistent with this. However, while in the 
undifferentiated CRSwNP group this Th2 cytokine signature could be further corroborated by 
accompanying increased ILC2 levels, differentiating the CRSwNP patient group on the basis 
of the different comorbidities indicates that the ILC2 population is not implicated in the 
pathophysiology of CRSwNP per se. Indeed, the levels of ILC2s in the mucosa of CRSwNP 
patients without comorbid allergy and/or asthma are not higher than in controls. However, 
ILC2 levels are increased in the inflamed mucosa of CRSwNP patients suffering from 
comorbid allergy and/or asthma. From these results, we speculate that in previous studies, in 
which the authors oppositely claimed striking amounts of ILC2s in inflamed nasal polyps [9-
11], mainly CRSwNP patients suffering from comorbid allergy and/or asthma must have 
been included, but these clinical data were not communicated. Our results once again 
emphasise the importance of detailed reporting and analysis of the patients’ clinical data in 
order to make correct interpretations. 
Opposite to CRSwNP, CRSsNP is characterized by a predominant Th1 milieu with 
pronounced levels of IFN-γ in the inflamed ethmoidal mucosa, histologically showing a 
fibrotic status of the inflamed tissue [1] with increased levels of transforming growth factor-
beta (TGF-β) as a critical factor involved in this remodelling process [18]. Despite of this 
Th1 signature, we here show that the mucosa of CRSsNP patients shows similar levels of 
ILC1s as observed for control subjects. Notably, the mucosa of CRSsNP patients retains 
clearly increased levels of ILC2s, but - in contrast to CRSwNP- the different comorbidities 
play no role herein. Recently, Forkel at al. reported a role for ILC2s in human liver fibrosis 
[19], which corroborates a previously suggested mechanism involving ILC2s in fibrosis 
development in the mouse liver [20]. These functional characteristics of ILC2s might be 
brought in agreement with the fibrotic status of the inflamed CRSsNP tissue, providing a 
possible functional explanation for the increased levels of ILC2s in CRSsNP. Indeed, it has 
been reported that TGFβ, an impotent mediator in the generation of fibrosis, enhances 
migration of ILC2s [21], supporting the increased presence of ILC2s in a Th1 disease such as 
CRSsNP.  Moreover, TGF-β has recently been reported to directly inhibit IL-33-induced IL-5 
and IL-13 production in ILC2s [22, 23]. 
 
The question then arises why ILC2s do not contribute to fibrosis in CRSwNP which displays 
an oedematous status. We propose that ILC2s in CRSsNP do not per se possess identical 
tissue-residency phenotypic properties than those present in CRSwNP tissue. Indeed, while 
CD117
-
 ILC2 can be found in control, CRSsNP and CRSwNP patient groups, our data show 
that the CD117
+
 ILC2 population is virtually absent in controls and CRSsNP, whereas it is 
explicitly present in the inflamed mucosa of CRSwNP patients. Thus the increased levels of 
the CD117
+
 ILC2s can be attributed to CRSwNP pathology, however yielding the most 
pronounced expansion in combination with allergy or asthma. With regard to the functional 
implications for ILC2s in CRSwNP, CD117 -also known as c-kit- is a receptor for stem cell 
factor (SCF) which is best known for its essential role in haematopoietic stem cell 
proliferation, survival and adhesion [24]. In a setting of diminished c-kit signals in mice, also 
ILC2s fail to develop [25]. In contrast to mice, in which mature ILC2 are reported to be 
exclusively CD117
+




 ILC2 populations are observed 
[4, 5], making functional interpretations less straightforward. Lim et al. observed no different 





 fractions of ILC2s [26], but the authors also reported that the expression of CD117 is 
affected by the culturing conditions, in which CD117
-
 cells can gain expression of CD117 
and vice versa.  Our results show that the phenotype of the native ex-vivo ILC2s is already 
altered after 3 hours culturing without active stimulation; ILC2s derived from CRSsNP -
natively lacking CD117 expression- develop a CD117
+
 fraction similar to what was natively 
observed in CRSwNP, while CD117
+
 ILC2s derived from CRSwNP tissue downregulate 
surface CD117 and CRTH2 expression upon stimulation with PMA/iono. These results show 
that the surface expression status of ILC2s relies on the specific local tissue conditions 
inherent to the different pathologies and that the characteristics of the ILCs in different 
pathologies cannot be accurately assessed by means of in vitro approaches using cultured 
cells and artificial stimulation methods. Recent findings by Li et al. on murine ILC2s also 
indicate that ILC2s are phenotypically more heterogeneous than previously thought, whereby 
surface expression levels of various markers frequently used to identify ILC2s were 
dependent on their mode of activation, highly variable over time, and differed between tissue 
compartments [27]. Also, when carefully inspecting the data from Bal et al. [10], the ILC2 





 ILC2s were previously regarded -by the same research group- to be 
less responsive in comparison to CD117
-
 ILC2s [9]. However, when the culture medium in 
their experiments was supplemented by IL-25, an equal amount of IL-13 was produced by 
both cell populations [9].  Because our data show that the levels of IL-25 are massively 
increased exclusively in the mucosa of CRSwNP patients, it can be assumed that the tissue 
specific environment of CRSwNP likewise yields functionally active CD117
+
 ILC2s.  
 
A second important phenotypic distinction between ILC2s present in CRSwNP and those in 
CRSsNP mucosa was found in the expression status of IL-1RI, the active receptor for IL1β. 
While CRSsNP and control tissues lack ILC2s that express the active IL-1β receptor, IL-1RI
+
 
ILC2s are clearly present in CRSwNP, where they are particularly high in patients with 
comorbid allergy or asthma. Initially, ILC2s have been indicated to unambiguously express 
IL-1RI [3, 5]. On the other hand, in a recent publication that assessed the heterogeneity of 
human CD127
+
 innate lymphoid cells by means of single-cell RNA sequencing, Bjorklund et 
al. observed no expression of IL-1RI in ILC2s of uninflamed tonsil tissue [13]. We here 
report that in the mucosa of human upper airways, the level of IL-1RI expression in ILC2s is 
dependent on the specific local tissue conditions inherent to the different pathologies or the 
normal mucosal airway physiology. Indeed, in controls and CRSsNP -regardless of the 
absence or presence of any comorbidities- virtually all ILC2s lack the expression of IL-1RI. 
In the CRSwNP patient group, IL-1RI expression is clearly higher in patients with comorbid 
allergy and/or asthma. Because ILC2 cells derived from peripheral blood already have a 
substantial surface expression of IL-1R1 [15], our data -corroborated by the lack in IL-1RI 
expression in uninflamed tonsil tissue as reported by Bjorklund et al. [13]- allows us to 
postulate that IL-1RI expression is downregulated in ILC2s at local tissue level under normal 
physiology and CRSsNP, probably by the lack of a specific trigger that maintains IL-1RI 
expression or by the presence of a trigger that downregulates its expression. Alternatively, the 
local mucosal tissue milieu of controls and CRsNP might only attract IL-1RI
-
 ILC2s from the 
blood while the tissue inflammatory environment in CRSwNP also enables the chemotaxis of 
the IL-1RI
+
 subset. Regardless of which rationale might be valid, parabiosis experiments 
indeed showed that ILCs residing in the non-lymphoid tissues are primarily maintained 
through self-renewal with minimal contribution from hematogenous precursors and also do 
not redistribute systemically [28], further corroborating that the local tissue environment is 
able to fine-tune the different ILC subsets into their final phenotype. What exactly triggers 
this clear-cut expression of the IL-1RI in CRSwNP, but not in CRSsNP, remains subject for 
further investigation. Functionally, IL-1RI engagement by IL-1β could directly affect human 
ILC2s by inducing low expression of the transcription factor T-BET and the cytokine 
receptor chain IL-12Rβ2, which subsequently allows IL-12 to induce the conversion of these 
activated ILC2s into an ILC1 phenotype [10, 15]. As we could not detect measurable IL-12 
levels in this tissue under any disease status, the importance of this functional plasticity in the 
human upper airway mucosa turns out to be unsure. Phenotypically, IL-1β is reported to 
significantly enhance expression of the receptors for IL-25, IL-33 and TSLP on ILC2 cells 
and to potentiate their responses to these cytokines. IL-1β-treated ILC2 cells produce 
significantly more Th2 cytokines in response to IL-33 and to IL-25 than ILC2s that did not 
receive IL-1β [10, 15]. The lack of IL-1RI expression on ILC2s in CRSsNP and its presence 
on ILC2s in CRSwNP is in agreement with the absence and presence of substantial IL-5 
production in the respective disease status.  
When comparing the levels of ILC2s with the levels of Th2 mediators in our study, it is clear 




 ILC2s are not in relationship with the concentration 





 ILC2s are the most likely to have contributed to the shaping of the Th2 environment 
in CRSwNP as could be concluded from the observation that this ILC2 subset clearly follows 
the pattern of IL-5 levels and the number of eosinophils that were assessed by means of ECP 
concentrations. The latter data corroborate a previous study that showed an interrelationship 
between eosinophilia and ILC2 levels in CRSwNP patients [29]. Our data additionally show 




 ILC2s, which also explains the lower 
eosinophil levels in CRSsNP in comparison to CRSwNP despite the increased levels of total 








We here show that the 3 ILC subsets are present in human upper airway mucosa. In non-
inflamed conditions, ILC1s are the most prominent subset. In CRSwNP, ILC1s are decreased 





fractions within the ILC2s, and taking comorbidities into account, we unveil the precise 




 ILC2s - 
exclusively present in CRSwNP - possess an interrelationship with Th2 cytokine and 





ILC2s are increased, yielding lower eosinophilia in this disease despite the high levels of 
ILC2s. These data moreover unveil for the first time that the CD117
-
 and the CD117
+
 
fractions within the human ILC2 population are not just random phenomena and that the IL-
1RI expression is not ubiquitous in ILC2s. Both are affected by local tissue conditions 
present under the specific inflammatory conditions. The specific ILC2 expression status 
could on its turn further shape the tissue specific environment as a consequence of the 
possible functional implications on CD117 and IL-1RI expression on the inflammatory 
mediator release by ILC2s.  
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FIG 1.  Relative number of the 3 ILC fractions in controls, CRSsNP and CRSwNP. Values 
are expressed as % ILCs of total living cells, and presented as Box-and-Whisker plots 
showing the minimum and the maximum value, the lower and the upper quartile, and the 
median. : vs control; : P < 0.05; : P < 0.01; : P < 0.001.  
 
FIG 2. Relative number of ILC1s in control, CRSsNP and CRSwNP subject groups separated 
on comorbidity status as indicated below the figure; -: absent, +: present. Values are 
expressed as % ILC1s of total living cells, and presented as Box-and-Whisker plots showing 
the minimum and the maximum value, the lower and the upper quartile, and the median. : 
vs control; *: vs the indicated subject group; *,: P < 0.05; **, : P < 0.01; : P < 
0.001.  
 
FIG 3. Relative number of ILC2s in control, CRSsNP and CRSwNP subject groups separated 
on comorbidity status as indicated below the figure; -: absent, +: present. Values are 
expressed as % ILC2s of total living cells, and presented as Box-and-Whisker plots showing 
the minimum and the maximum value, the lower and the upper quartile, and the median. : 
vs control; *: vs the indicated subject group; *, : P < 0.05; : P < 0.01; ***, : P 
< 0.001. 
 
FIG 4. Relative number of NCR
-
 (A) and NCR
+
 (B) ILC3s in control, CRSsNP and 
CRSwNP subject groups separated on comorbidity status as indicated below the figure; -: 
absent, +: present. Values are expressed as % ILC3s of total living cells, and presented as 
Box-and-Whisker plots showing the minimum and the maximum value, the lower and the 
upper quartile, and the median. : vs control, P < 0.05. 
 
FIG 5. Relative number of CD117
-
 ILC2s (A and B) and CD117
+
 ILC2s (A and C) in 
control, CRSsNP and CRSwNP subject groups separated on comorbidity status as indicated 
below the figure; -: absent, +: present. Values are expressed as % ILC2s of total living cells, 
and presented as Box-and-Whisker plots showing the minimum and the maximum value, the 
lower and the upper quartile, and the median. : vs control; *: vs the indicated subject 
group; *, : P < 0.05; **, : P < 0.01; ***, : P < 0.001. 
 
FIG 6. Relative number of IL-1RI
-
 ILC2s (A and B) and IL-1RI 
+
 ILC2s (A and C) in 
control, CRSsNP and CRSwNP subject groups separated on comorbidity status as indicated 
below the figure; -: absent, +: present. Values are expressed as % ILC2s of total living cells, 
and presented as Box-and-Whisker plots showing the minimum and the maximum value, the 
lower and the upper quartile, and the median. : vs control; *: vs the indicated subject 
group; *, : P < 0.05; **, : P < 0.01; ***, : P < 0.001. 
 
FIG 7. Quantification of tissue IL-4 (A), IL-5 (B), ECP (C) and IL-25 (D) protein levels by 
means of Luminex multiplex (A, B and D) or UniCAP (C) in control, CRSsNP and CRSwNP 
subject groups separated on comorbidity status as indicated below the figure; -: absent, +: 
present. Values are expressed pg/g tissue, and presented as Box-and-Whisker plots showing 
the minimum and the maximum value, the lower and the upper quartile, and the median. : 
vs control; *: vs the indicated subject group; *, : P < 0.05; **, : P < 0.01; : P < 
0.001. 
  
      Table I. Patients’ clinical data  
      
  control CRSsNP CRSwNP 
 
Clinical data  
 
number of subjects 29 17 35 









Allergy + / asthma - 6 5 8 
Allergy - /Asthma + 6 0 6 
Allergy + /asthma + 5 5 9 
AERD 0 0 0 
      
      
CRSsNP: chronic rhinosinusitis without nasal polyps;  CRSwNP: chronic rhinosinusitis with nasal polyps; 















































n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +





























n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +





































n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
12    6    6    5 7    5    0    5 12    8    6    9
-    +    -    +






























n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
12    6    6    5 7    5    0    5 12    8    6    9
-    +    -    +






























n   =
allergy
asthma
-         +         -         +
-         -         +         +
-         +         -         +
-         -         +         +
-        +         -         +
-         -         +         +



































n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +







































n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +









































n   =
allergy
asthma
-         +         -         +
-         -         +         +
-         +         -         +
-         -         +         +
-        +         -         +
-         -         +         +



































n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +





































n   =
allergy
asthma
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +
-    +    -    +
-    -    +    +






































Tissues were obtained at the Department of Otorhinolaryngology, Ghent University Hospital, 
Belgium during routine endonasal sinus surgery and approved by the local ethical committee. 
All patients gave their written informed consent before collecting material. All patients 
stopped oral and topical application of corticosteroids for at least 1 month before surgery. 
The diagnosis of chronic sinus disease was based on history, clinical examination, nasal 
endoscopy, and computed tomography of the paranasal cavities according to the current 
European [1, 2] and American Guidelines [3]. The patients’ clinical data can be found in 
Table 1 of the main document. 
 
Single cells preparation 
1.5g of freshly resected human nasal mucosa was transferred to 10 ml tissue culture medium 
(RPMI 1640 (Invitrogen, Ghent, Belgium)), containing 2 mM LGlutamine (Invitrogen), 
antibiotics (50 IU/ml penicillin and 50 μg/ml streptomycin) (Invitrogen) and 2% FBS (Fetal 
Bovine Serum, Invitrogen) and roughly fragmented with scissors into small pieces, followed 
by a mixing step in the Gentle MACs (Miltenyi Biotec, Leiden, The Netherlands). Gentle 
MACs tubes with tissue were centrifuged for 5 min at 300 g and supernatant was discarded 
and replaced by RPMI medium containing 2 mg/ml collagenase (Worthington, USA) and 
0.04 mg/ml DNAse1 (Roche Diagnostics, Belgium). After a 45 min incubation period at 37 
°C, an additional mixing step in the GentleMACs was performed. The cell suspension was 
dispersed and passed through a 70 μm cell strainer (BD Bioscience, Erembodegem, 
Belgium). Red blood cells were lysed by resolving the pellet in Versalyse (Beckman Coulter, 
Suarlée, Belgium) and cells were incubated for 10 min at RT and after centrifugation the cell 
pellet was dissolved in RPMI with 2% FBS. For the descriptive part of the study, the single 
cells were used immediately for flow cytometry staining as described in the paragraph “Flow 
cytometry staining” below and in the main document. For the functional part of the study, the 
single cells were processed as reported in the paragraph “in vitro assessment of the functional 
responses by freshly isolated ILC2s” in both the main document.  
  
Flow cytometry staining 
Flow cytometry data were acquired on an LSR II (BD, Erenbodegem, Belgium) and were 
analyzed with FlowJo software (TreeStar). The following antibodies to human proteins were 
used for staining freshly resected tissues: fluorescein isothiocyanate (FITC)-conjugated anti-
CD3 (BW264/56), anti-CD11c (MJ4-27G12), anti-CD19 (LT19), anti-CD34 (AC136), anti-
CD303 (AC144), anti-FceRIa (AER-37) (all from BioLegend, San Diego, CA, USA), anti-
CD94 (DX22) (ebioscience, San Diego, CA, USA), anti-CD14 (MφP9) (BD), phycoerythrin 
(PE)-conjugated anti-ILRI (Polyclonal Goat IgG) (R&D, Oxon, United Kingdom), PECy7-
conjugated anti-CD117 (104D2) (ebioscience, San Diego, CA, USA), allophycocyanin 
(APC)-conjugated anti-CRTH2 (BM16) (Biolegend), APCCy7-conjugated anti-CD45 (2D1) 
(Miltenyi, Leiden, The Netherlands), peridinin chlorophyll (PerCP) efluor 710-conjugated 
anti-NKp44 (44.189) (ebioscience) and brilliant violet (BV)421-conjugated anti-CD127 
(A019D5) (Biolegend). 
 
To investigate the contradictory data present in the literature regarding the expression of IL-
1RI on ILC2s [4-6] and to evaluate the relative contributions of the documented CD117 
positive and negative fractions within the ILC2 population [4, 7], we extended our gating 
strategy including antibodies against IL-1RI and CD117 in the ILC2 gating strategy. as 
shown in figures E1 and E2 in this Online Repository.  
 
After in vitro stimulation, additional IL-5 cytokine expression was assessed using BV421-
conjugated anti-IL5 (TRFK5) (Biolegend). For labeling cells of the in vitro series, all FITC-
conjugated antibodies remained identical to the staining on the freshly resected tissues. The 
other antibodies in this series were conjugated as follows: PECy7-conjugated anti-CD117 
(104D2) (ebioscience, San Diego, CA, USA), allophycocyanin (APC)-conjugated anti-
CRTH2 (BM16) (Biolegend), APCFire-conjugated anti-CD45 (BM16) (Biolegend) and 
Horizon BV510-conjugated anti-CD161 (HP-3G10) (Biolegend). 
 
Fluorescence Minus One (FMO) data for CRTH2, CD117, IL1RI and NKp44 were used in 
the gating strategy ensuring accurate setting of gates for correct determinations of positive 
and negative populations. This is also indicated in figure E1 as grey overlays in the 
histograms explaining the gating strategy used in this study. During protocol optimization, 




Snap-frozen tissue specimens were weighed and suspended in a 10 times volume of 0.9% 
NaCl solution with protease inhibitor Complete Roche (Mannheim, Germany). In order to 
prepare soluble protein fractions, the frozen tissue was pulverized by means of a mechanical 
TissueLyser LT (Qiagen, Hilden, Germany) at 50 oscillations per second for 2 minutes in 
pre-chilled eppendorf tubes. The tissue homogenates were centrifuged at 1800 g for 5 





In vitro assessment of the functional responses by freshly isolated ILC2s  
After 3h on 37°C in the presence of IL-2 without stimulation, the single cell fractions from 
nasal polyps of CRSwNP patients (all allergic or asthmatic) contained 0.08 ± 0.05 % CD117
+
 
ILC2s and 0.09 ± 0.04 % CD117
-
 ILC2s (n=3) of the living cell fraction, being similar to 
what was observed for the ex-vivo part of the study on 35 CRSwNP patients (see fig 5 in the 
main document). However, in PMA/Ionomycin stimulated single cell fractions from the same 
patients the number of CD117
+
 ILC2s was almost abolished to 0.01 ± 0.004 % of living cells, 
while the number of CD117
-
 ILC2s remained unaffected at 0.08 ± 0.02 % of living cells. The 
latter cell fraction contained no IL5+ cells at baseline conditions, while in the 
PMA/Ionomycin stimulated single cell fraction, 16.80 ± 5.11 % of the cells were IL-5 
positive.  
The % of counted cells in the ILC1 gate increased from 0.05 % ± 0.02 % of living cells under 
basal non-stimulated conditions to 0.19 % ± 0.08 % of living cells when the cells were 
stimulated by PMA/Ionomycin. While under basal conditions, the intracellular IL-5 
expression in these cells was virtually absent, the stimulated cells in the ILC1 gate contained 
15,5 ± 3.66 % IL-5
+
 cells. The cells found in the ILC1 gate could be recovered to the ILC2 
fraction by intracellular staining for CRTH2 and CD117 in addition to the membrane staining 
for these markers; by doing so, the number of CD117+ ILC2 cells restored to 0.05 ± 0.01 % 
of living cells (of which 12.63 ± 4.05 % were IL-5
+
), while the number of cells in the ILC1 
gate reduced again to 0.04 ± 0.01 % of living cells, all lacking intracellular IL-5 expression.  
After 3h on 37°C in the presence of IL-2 without stimulation, the single cell fractions from 
nasal polyps of CRSsNP patients contained an equal number of CD117
+
 ILC2s and CD117
-
 
ILC2s (0.04 ± 0.005 % vs 0.03 ± 0.002 % of the living cell fraction (n=2) respectively, which 
contrasts the virtual absence of CD117+ ILC2s in freshly resected tissue of CRSsNP patients 




































































 for the NCR
+
 fraction. The 
Fluorescence Minus One (FMO) for CRTH2 (grey overlay) is indicated in the histogram 
identifying the ILC2 population. FMO data for CD117 and IL1RI are presented as grey dot 
plots next to the dot plot assessing the levels of CD117 and IL1RI expression within the ILC2 
population and the dot plot identifying the ILC1, NCR
-
 ILC3 and NCR
+
 ILC3 populations are 
accompanied by FMO data for CD117 and NKp44.  
 
FIG E2. Relative number of CD45
+
 in control CRSsNP and CRSwNP subject groups 
expressed as a % of total living cells (A) and relative number of living cells as a % of all 
events (B). Data are presented as Box-and-Whisker plots showing the minimum and the 
maximum value, the lower and the upper quartile, and the median. ***: P < 0.001, ns = not 
significant. 
 
FIG E3.  Relative number of the 3 ILC fractions in controls, CRSsNP and CRSwNP. Values 
are expressed as % ILCs of CD45
+
 cells, and presented as Box-and-Whisker plots showing 
the minimum and the maximum value, the lower and the upper quartile, and the median. : 
vs control;  : P < 0.01; : P < 0.001.  
 
FIG E4. Representative dot plots of the gating step assessing the expression of CD117 and 
IL1RI on ILC2 cell population in controls (upper panel), CRSsNP (middle panel) and 
CRSwNP (lower panel). In the examples all individuals suffered from allergic asthma. 
Fluorescence Minus One (FMO) for CD117 and IL1RI are presented as grey overlays in the 
small dot plots at the right as indicated in the figure.  
 

















 in control, CRSsNP and CRSwNP subject groups separated on comorbidity 
status as indicated below the figures. Values are expressed as % ILC2 subsets of total living 
cells, and presented as Box-and-Whisker plots showing the minimum and the maximum 
value, the lower and the upper quartile, and the median. 
 
 
FIG E6. Graphs showing the individual data points of the ILC levels that were presented in 
figures 1 to 7 of the main document as Box-and-Whisker plots.   
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